Results 161 to 170 of about 3,107 (205)
EE424 Societal Costs of Spinal Muscular Atrophy Type 1 for Patients Treated with Onasemnogene Abeparvovec or Nusinersen in the United Kingdom [PDF]
J. Kleintjens +6 more
openalex +1 more source
Onasemnogene Abeparvovec: Post-infusion Efficacy and Safety in Patients With Spinal Muscular Atrophy (SMA)-A Fondazione Policlinico Gemelli IRCCS Experience. [PDF]
Favia M +5 more
europepmc +1 more source
Emerging thrombotic disorders associated with virus-based innovative therapies: from VITT to AAV-gene therapy-related thrombotic microangiopathy [PDF]
Benemei, Silvia, Marcucci, Rossella
core +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
L O Badalyan Neurological Journal
Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are ...
D. A. Fisenko +12 more
semanticscholar +1 more source
Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are ...
D. A. Fisenko +12 more
semanticscholar +1 more source

